Phibro Animal Health CORP Form 4 insider transactions

Phibro Animal Health's President and CEO, Jack Bendheim, and BFI Co., LLC, sold a total of 27,845 shares of Class A Common Stock in pre-planned transactions.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC reported sales of Class A Common Stock and conversion of Class B shares under a Rule 10b5-1 plan.

Phibro Animal Health Corporation's President and CEO, Jack Bendheim, along with BFI Co., LLC, reported the sale of 213 shares of Class A Common Stock at $40.16 per share under a pre-arranged trading plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, sold 328 shares of Class A Common Stock for approximately $40.09 per share under a pre-arranged 10b5-1 trading plan.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold 5,752 Class A shares under a 10b5-1 plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold 4,808 shares of Class A Common Stock for approximately $192,760 through a pre-arranged 10b5-1 trading plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, converted Class B shares to Class A and subsequently sold a portion of Class A shares through a pre-arranged trading plan.

Phibro Animal Health's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold 7,040 shares of Class A Common Stock in late November and early December 2025.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold over $541,000 worth of Class A Common Stock in pre-planned transactions.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, and BFI Co., LLC, sold Class A Common Stock totaling 3,520 shares through a pre-arranged 10b5-1 trading plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, along with BFI Co., LLC, reported planned conversions of Class B to Class A common stock and subsequent sales in November 2025 under a pre-arranged 10b5-1 trading plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, and BFI Co., LLC, executed pre-planned sales of Class A Common Stock totaling 30,337 shares.

Phibro Animal Health Corporation's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold over 41,000 shares of Class A Common Stock for approximately $1.89 million through a pre-arranged trading plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, along with BFI Co., LLC, reported sales of Class A Common Stock totaling 7,040 shares under a pre-arranged 10b5-1 trading plan.

Phibro Animal Health's President and CEO, Jack Bendheim, reported the sale of 10,560 Class A Common Stock shares through a pre-arranged 10b5-1 trading plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, and BFI Co., LLC, reported sales of Class A Common Stock totaling 18,899 shares under a Rule 10b5-1 trading plan.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC reported sales of Class A Common Stock and conversion of Class B shares into Class A shares under a 10b5-1 plan.

Phibro Animal Health's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold 20,664 shares of Class A Common Stock for approximately $834,000 under a pre-arranged 10b5-1 trading plan.

Phibro Animal Health CEO Jack Bendheim, through BFI Co., LLC, sold 7,022 Class A shares and converted 30,000 Class B shares to Class A.

Phibro Animal Health's President and CEO, Jack Bendheim, through BFI Co., LLC, executed pre-planned sales of Class A Common Stock totaling 21,120 shares.

Phibro Animal Health Corp's Chief Operating Officer, Larry Lee Miller, was granted 5,184 restricted stock units as part of his compensation.

Phibro Animal Health Corp. granted 3,447 restricted stock units to Senior Vice President, General Counsel, and Corporate Secretary Judith Weinstein, vesting over three years.

Phibro Animal Health Corp's Chief Financial Officer, Glenn David, was granted 4,845 restricted stock units, aligning his interests with shareholders.

Phibro Animal Health Corp. director Jonathan Bendheim was granted 3,268 restricted stock units, aligning his interests with shareholders.

Phibro Animal Health Corp. granted 3,964 restricted stock units to Daniel M. Bendheim, Executive VP of Corporate Strategy, vesting over three years.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, was granted 16,840 restricted stock units, vesting over three years.

Phibro Animal Health Corp. Senior VP Lisa Ann Escudero was granted 2,152 restricted stock units, vesting over three years.

Phibro Animal Health Corp's VP of Finance and Treasurer, Anthony Andolino, was granted 1,793 restricted stock units vesting over three years.

E. Thomas Corcoran, a director at Phibro Animal Health Corp, reports purchasing 5,000 shares of Class A Common Stock at an average price of $22.1 and disposing of 30,000 shares on February 24, 2025.

Glenn David, CFO of Phibro Animal Health Corp, settles 30,000 Class A Common Stock restricted stock units.